[
  {
    "question": {
      "question_id": "cs03_q11_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "longitudinal",
      "prompt": "What is the emerging safety profile of LNS-4821, and which patient subgroup is most affected?",
      "ground_truth": {
        "canonical_answer": "Hepatotoxicity in the statin co-administered subgroup. ALT elevations reaching 2-3x ULN across multiple sites, with two subjects meeting Hy's Law criteria. Non-statin patients remain stable. The cross-site distribution rules out the Site 07 equipment hypothesis.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q11_longitudinal",
      "answer_text": "I could not find any information regarding the safety profile of LNS-4821 or the patient subgroup most affected. The memory system returned no results for this query.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_1cf95623146d44af9476edb9",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 527
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_1cf95623146d44af9476edb9",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_0675000eafe9425c9e05ae7d",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 safety profile patient subgroup",
                "limit": 10
              }
            }
          ],
          "tokens_used": 611
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_0675000eafe9425c9e05ae7d",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I could not find any information regarding the safety profile of LNS-4821 or the patient subgroup most affected. The memory system returned no results for this query.",
          "tokens_used": 660
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1798,
      "wall_time_ms": 3613.9828669838607,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q12_severity",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "severity_assessment",
      "prompt": "How would you assess the severity of the hepatic signal and the urgency of protocol intervention?",
      "ground_truth": {
        "canonical_answer": "High severity. Two subjects have met Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN), which is a recognized indicator of potential drug-induced liver injury. The signal is escalating and protocol amendment is urgent to prevent further SAEs.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q12_severity",
      "answer_text": "I could not find any information in the memory system regarding the assessment of hepatic signal severity or the urgency of protocol intervention [ref_id: none]. Therefore, I am unable to provide an evaluation on this topic based on the available data.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_f0aaec65833d4deebdfdefe9",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 522
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_f0aaec65833d4deebdfdefe9",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9109ce1f2685444f950cf993",
              "name": "memory_search",
              "arguments": {
                "query": "hepatic signal severity assessment and protocol intervention urgency"
              }
            }
          ],
          "tokens_used": 598
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9109ce1f2685444f950cf993",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I could not find any information in the memory system regarding the assessment of hepatic signal severity or the urgency of protocol intervention [ref_id: none]. Therefore, I am unable to provide an evaluation on this topic based on the available data.",
          "tokens_used": 660
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1780,
      "wall_time_ms": 5029.961077030748,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q15_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "negative",
      "prompt": "Is there evidence of an immune-mediated reaction or immunogenicity issues with LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Immunogenicity markers and antibody responses are not related to the hepatic safety signal. The mechanism is a pharmacokinetic drug-drug interaction via CYP3A4, not an immune-mediated reaction.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_005",
          "clinical_signal_03_ep_012"
        ],
        "key_facts": [
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q15_negative",
      "answer_text": "There is no evidence in the available memory regarding immune-mediated reactions or immunogenicity issues with LNS-4821.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_6dc8870138034a5090023b13",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 526
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_6dc8870138034a5090023b13",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9db1722eecc04b16891c221e",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 immune-mediated reaction immunogenicity",
                "limit": 10
              }
            }
          ],
          "tokens_used": 612
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9db1722eecc04b16891c221e",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "There is no evidence in the available memory regarding immune-mediated reactions or immunogenicity issues with LNS-4821.",
          "tokens_used": 652
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1790,
      "wall_time_ms": 5128.356516943313,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q17_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "temporal",
      "prompt": "How rapidly are ALT values escalating in the affected subgroup?",
      "ground_truth": {
        "canonical_answer": "ALT values in the statin subgroup have progressed from baseline normal (15-35 U/L) through subtle elevation (45-65 U/L) to clinically significant levels (80-120 U/L, 2-3x ULN) over the course of the signal and escalation phases. The rate of increase has accelerated.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q17_temporal",
      "answer_text": "I could not find any information regarding the rate at which ALT values are escalating in the affected subgroup [ref_id].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9f23010f9dd24c89b5cb9892",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 515
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9f23010f9dd24c89b5cb9892",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_28dd074dd243408f8ea266fa",
              "name": "memory_search",
              "arguments": {
                "query": "ALT values escalation rate in affected subgroup"
              }
            }
          ],
          "tokens_used": 588
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_28dd074dd243408f8ea266fa",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I could not find any information regarding the rate at which ALT values are escalating in the affected subgroup [ref_id].",
          "tokens_used": 625
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1728,
      "wall_time_ms": 5760.68002008833,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q21_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "distractor_resistance",
      "prompt": "Are VAS pain scores or functional assessments correlating with the laboratory abnormalities?",
      "ground_truth": {
        "canonical_answer": "No. Pain endpoints are stable and unrelated to the hepatic safety signal. The ALT elevations correlate with statin co-administration, not pain or functional measures.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006",
          "clinical_signal_03_ep_017"
        ],
        "key_facts": [
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q21_distractor",
      "answer_text": "The available information does not indicate any correlation between VAS pain scores or functional assessments and laboratory abnormalities [ref_id: none]. No relevant documents were found addressing this specific relationship.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_dfa47a69ff5740f5bd18fd85",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 519
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_dfa47a69ff5740f5bd18fd85",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_84d263c9890f41b18f83035b",
              "name": "memory_search",
              "arguments": {
                "query": "VAS pain scores correlation with laboratory abnormalities"
              }
            }
          ],
          "tokens_used": 592
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_84d263c9890f41b18f83035b",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_250524a8bd1841ceafaca7a3",
              "name": "memory_search",
              "arguments": {
                "query": "functional assessments correlation with laboratory abnormalities"
              }
            }
          ],
          "tokens_used": 630
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_250524a8bd1841ceafaca7a3",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The available information does not indicate any correlation between VAS pain scores or functional assessments and laboratory abnormalities [ref_id: none]. No relevant documents were found addressing this specific relationship.",
          "tokens_used": 679
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 2420,
      "wall_time_ms": 4971.297804033384,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q22_counterfactual",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "counterfactual",
      "prompt": "If the ALT elevations were caused by a viral hepatitis outbreak among trial subjects, what pattern would you expect? Does the data match?",
      "ground_truth": {
        "canonical_answer": "Viral hepatitis would show clustered onset at specific sites, associated symptoms (fatigue, jaundice), and positive viral serologies. Instead, the elevations are distributed across sites and correlate with statin co-administration, not geography or viral exposure. The pattern is consistent with a pharmacokinetic interaction, not infection.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q22_counterfactual",
      "answer_text": "I cannot find any information regarding a pattern of ALT elevations caused by a viral hepatitis outbreak among clinical trial subjects, nor any data to compare against such a pattern. The available memory system does not return relevant results for this query [ref_id: none]. Therefore, I cannot determine whether the data matches the expected pattern.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9a5fb48382814a839a26112c",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 534
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9a5fb48382814a839a26112c",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_25eb1b1687e34e35b0b22e6f",
              "name": "memory_search",
              "arguments": {
                "query": "ALT elevations viral hepatitis outbreak pattern in clinical trial data"
              }
            }
          ],
          "tokens_used": 608
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_25eb1b1687e34e35b0b22e6f",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I cannot find any information regarding a pattern of ALT elevations caused by a viral hepatitis outbreak among clinical trial subjects, nor any data to compare against such a pattern. The available memory system does not return relevant results for this query [ref_id: none]. Therefore, I cannot determine whether the data matches the expected pattern.",
          "tokens_used": 686
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1828,
      "wall_time_ms": 4330.833451007493,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q23_null",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "null_hypothesis",
      "prompt": "How many protocol deviations were reported at Site 03 in the most recent weekly summary?",
      "ground_truth": {
        "canonical_answer": "The protocol deviation count as documented in the weekly site summary.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_018"
        ],
        "key_facts": []
      }
    },
    "answer": {
      "question_id": "cs03_q23_null",
      "answer_text": "I could not find any information regarding protocol deviations reported at Site 03 in the most recent weekly summary [ref_id].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_a7256a86407343bf92953163",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 522
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_a7256a86407343bf92953163",
              "content": "{\"search_modes\": [\"semantic\"], \"filter_fields\": [], \"max_results_per_search\": 10, \"supports_date_range\": false, \"extra_tools\": []}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_e193f1b50d0740bf93a785b8",
              "name": "memory_search",
              "arguments": {
                "query": "Site 03 protocol deviations most recent weekly summary"
              }
            }
          ],
          "tokens_used": 598
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_e193f1b50d0740bf93a785b8",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I could not find any information regarding protocol deviations reported at Site 03 in the most recent weekly summary [ref_id].",
          "tokens_used": 637
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 1757,
      "wall_time_ms": 2788.62571506761,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  }
]